These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Survival and the value of adjuvant chemotherapy in esophageal squamous cell carcinoma patients with lymphatic metastasis].
    Author: Qi Z, Wang YX, Yang Q, Li J, Yao JF, He M.
    Journal: Zhonghua Zhong Liu Za Zhi; 2017 Aug 23; 39(8):628-633. PubMed ID: 28835088.
    Abstract:
    Objective: To investigate the prognosis and the value of adjuvant chemotherapy in esophageal squamous cell carcinoma (ESCC) patients with lymphatic metastasis. Methods: From Jan, 2008 to Dec, 2011, 329 patients with ESCC who underwent two-field radical resection(R0), had lymphatic metastasis and survived over three months were enrolled in this study. There were 246 males and 83 females. The median age was 61 years-old. Site of lesion was located at upper- in 23, middle- in 226 and lower-thoracic segment in 80 patients. There were 114 patients treated with surgery alone and 215 patients with adjuvant chemotherapy. Prognostic factors including adjuvant chemotherapy were assessed in ESCC patients with lymphatic metastasis. Results: In 329 ESCC patients with lymphatic metastasis, the 1-, 3-, 5-years overall survival (OS) rate and progress-free survival (PFS) rate were 74.5%, 31.7%, 24.5%, and 55.1%, 27.8%, 24.2%, respectively. Median OS and PFS were 22 and 15 months, respectively. Multivariate analysis showed that, site of lesion and disease stage were independent factors for OS and PFS (P<0.05). Adjuvant chemotherapy was also an independent prognostic factor for OS (P<0.05). Subgroup analysis showed that adjuvant chemotherapy could improve OS mainly in patients of males, ages≤60, tumor length <6 cm, well- or mediated differentiated squamous cell carcinoma, stage pT3, pN2 and ⅢB (P<0.05). Conclusions: ESCC patients with lymphatic metastasis had poor prognosis. Site of lesion and disease stage were important prognositic factors for survival. Adjuvant chemotherapy could improve survival in specific patients. 目的： 分析食管鳞癌(ESCC)术后病理淋巴结阳性(pN阳性)患者的预后及其术后化疗的作用。 方法： 收集2008年至2011年行胸腹两野食管癌根治术、术后pN阳性、生存时间≥3个月的胸段ESCC患者329例。其中男246例，女83例，中位年龄61岁。原发肿瘤位于胸上、中、下段分别为23、226和80例。单纯手术114例，术后化疗215例。分析影响胸段ESCC术后pN阳性患者生存的因素，以及术后化疗对患者生存的影响。 结果： 329例胸段ESCC术后pN阳性患者的1、3、5年生存率和1、3、5年无进展生存率分别为74.5%、31.7%、24.5%和55.1%、27.8%、24.2%，中位生存时间和中位无进展生存时间分别为22和15个月。多因素分析显示，原发肿瘤位置、TNM分期和术后化疗是影响患者总生存的独立因素(均P<0.05)，原发肿瘤位置和TNM分期是影响患者无进展生存的独立因素(均P<0.05)。亚组分析显示，术后化疗主要提高男性、年龄≤60岁、肿瘤长度<6 cm、中高分化、pT3期、pN2期和ⅢB期ESCC患者的生存时间(均P<0.05)。 结论： ESCC术后pN阳性患者的预后不佳，TNM分期和原发肿瘤位置是影响其生存的主要因素，术后辅助化疗能提高部分患者的生存时间。.
    [Abstract] [Full Text] [Related] [New Search]